CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical
technology company with a current focus on the diagnosis and
monitoring of cardiac arrhythmias, today reported results for the
first quarter ended March 31, 2010.
First Quarter 2010 Highlights
- Achieved gross margin of 63% on
revenues of $32 million
- Experienced improved results
with a loss of $0.23 per diluted share, a $0.44 improvement over
the fourth quarter 2009; on an adjusted basis the loss per diluted
share was $0.13, a 46% improvement over the fourth quarter
2009
- MCOTTM patient volume increased
23% to over 30,000 patients compared to the first quarter 2009
- Commercial reimbursement rates
in the first quarter 2010 remained stable with the fourth quarter
2009 rates
- Reduced DSO to 113 days, a
reduction of 9 days compared to the fourth quarter 2009
- Secured 14 new payor contracts,
covering over one million lives, for total covered lives of over
200 million
- Ahead of plan to achieve
previously announced $15 million in cost reductions
- Received FDA approval of our
next generation MCOTTM platform
- $45 million in cash and no debt
as of March 31, 2010
President and CEO Commentary
Randy Thurman, Chairman, President and Chief Executive Officer
of CardioNet, commented: “Our strong operating results for the
first quarter 2010 included significant improvements compared to
the fourth quarter 2009 in both operating margin and gross margin.
We reported strong revenues at $31.8 million with stable
reimbursement and MCOTTM volume growth of 23% over the first
quarter 2009. While our operating and gross margins exceeded our
projections, we experienced lower than anticipated volume growth,
which we believe is largely due to increased patient deferrals
resulting from rising insurance deductibles and co-pays. In
addition, with the implementation of our new electronic payor
connectivity system, we were better able to identify patients who
did not have coverage for our service. While this decreased the
number of patients put on service, it improved profitability. In
response to the lower than anticipated volume, we accelerated the
implementation of productivity and cost improvement initiatives
across the organization.
“The market potential for MCOTTM remains strong. We believe we
can drive higher adoption and utilization of MCOTTM with the
addition of a contracted sales organization to complement our
existing sales force, which is the largest and most experienced in
wireless medicine. Throughout 2010, we expect to gain share in the
cardio thoracic surgery and neurology markets, driven by new
specialized physician reporting enhancements. During the first
quarter, we launched a new marketing campaign to increase physician
awareness of the benefits of our product. In addition, numerous
clinical studies are currently underway which will add to the
unparalleled body of clinical support for MCOTTM, which today
stands at 30 published abstracts and peer reviewed papers.
“FDA clearance of our next generation MCOTTM platform is a major
milestone for the Company and we expect to launch this new
technology in the latter part of 2010. This advanced MCOTTM
platform will utilize our patented core technology with expanded
capabilities, an improved patient interface and a smaller and
lighter body sensor. In addition, we expect to be able to deliver
these enhancements at a lower product cost which will contribute
incrementally to our on-going cost reduction strategy. We look
forward to this innovation in our technology and the impact it will
have in the marketplace.
“While the Company is ahead of schedule to achieve $15 million
in cost savings and on track to achieve positive EBITDA during the
second half of the year, we are closely monitoring volume growth.
We are continuing our efforts to obtain a national reimbursement
rate from CMS and secure contracts with the few remaining large
commercial payors. Though we still face the challenge posed by the
unexpected decision by Highmark Medicare Services in July 2009 to
cut the reimbursement rate for mobile cardiac telemetry by
one-third as of September 2009, our key focus remains on delivering
unparalleled service and quality of care to the physicians and
patients that we serve while we work to improve the cost structure
of the company. While we still have much to accomplish, we feel
that we have made significant progress and remain optimistic about
the future of CardioNet.”
First Quarter Financial Results
Revenues for the first quarter 2010 were $31.8 million compared
to $35.7 million in the first quarter 2009, a decrease of $3.9
million. Increased MCOTTM patient volume drove additional revenues,
but was offset by the impact of the Medicare rate reduction as well
as lower commercial reimbursement versus the prior year. For the
first quarter 2010, the Company’s payor mix for revenue was 33%
Medicare and 67% commercial. Gross profit declined to $20.1 million
in the first quarter 2010, or 63.1% of revenues, compared to $23.9
million in the first quarter 2009, or 66.9% of revenues.
On a GAAP basis, operating loss was $5.4 million in the first
quarter 2010 compared to operating loss of $1.3 million in the
first quarter 2009. Excluding $2.4 million of expense related to
restructuring and other charges, adjusted operating loss was $3.0
million in the first quarter 2010. This compares to adjusted
operating income of $1.6 million in the first quarter 2009, which
excludes $3.0 million of expense related to restructuring and other
charges in the prior year period.
On a GAAP basis, net loss for the first quarter 2010 was $5.4
million, or a loss of $0.23 per diluted share, compared to a net
loss of $0.7 million, or a loss of $0.03 per diluted share, for the
first quarter 2009. Excluding expenses related to restructuring and
other charges, adjusted net loss for the first quarter 2010 was
$3.0 million, or a loss of $0.13 per diluted share. This compares
to adjusted net income of $1.0 million, or $0.04 per diluted share,
for the first quarter 2009, which excludes the impact of
restructuring and other charges.
Heather Getz, CardioNet’s Chief Financial Officer, commented:
“We made significant progress in our cost reduction initiatives
with more than $3.0 million in savings during the first quarter
2010. The cost reductions contributed to a gross margin improvement
of 220 basis points and a seven percentage point improvement in
adjusted operating margin compared to the fourth quarter 2009.
“Our balance sheet remains strong with $45 million in cash and
no debt. In the first quarter, our DSO was 113 days, an improvement
of 9 days versus the fourth quarter 2009. We expect continued
improvement during the remainder 2010.
“We are pleased with our results to date and remain confident in
our ability to achieve the Company’s financial goals for 2010. We
will continue to look for additional opportunities to streamline
our operations and improve our profitability.”
Conference Call
CardioNet, Inc. will host an earnings conference call on
Wednesday, April 28, 2010, at 5:00 PM Eastern Time. The call will
be simultaneously webcast on the investor information page of our
website, www.cardionet.com. The call will be archived on our
website and will also be available for two weeks via phone at
888-286-8010, access code 25578622.
About CardioNet
CardioNet is the leading provider of ambulatory, continuous,
real-time outpatient management solutions for monitoring relevant
and timely clinical information regarding an individual’s health.
CardioNet’s initial efforts are focused on the diagnosis and
monitoring of cardiac arrhythmias, or heart rhythm disorders, with
a solution that it markets as Mobile Cardiac Outpatient TelemetryTM
(MCOT™). More information can be found at
http://www.cardionet.com.
Forward-Looking Statements
This press release includes certain forward-looking statements
within the meaning of the "Safe Harbor" provisions of the Private
Securities Litigation Reform Act of 1995 regarding, among other
things, our growth prospects, the prospects for our products and
our confidence in the Company’s future. These statements may be
identified by words such as “expect,” “anticipate,” “estimate,”
“intend,” “plan,” “believe,” ”potential,” “promises” and other
words and terms of similar meaning. Such forward-looking statements
are based on current expectations and involve inherent risks and
uncertainties, including important factors that could delay,
divert, or change any of them, and could cause actual outcomes and
results to differ materially from current expectations. These
factors include, among other things, the success of our efforts to
address the operational issues, including cost savings initiatives,
changes to reimbursement levels for our products and the success of
our attempts to achieve a national rate from CMS, the success of
our sales and marketing initiatives, our ability to attract and
retain talented executive management and sales personnel, our
ability to identify acquisition candidates, acquire them on
attractive terms and integrate their operations into our business,
the commercialization of new products, market factors, internal
research and development initiatives, partnered research and
development initiatives, competitive product development, changes
in governmental regulations and legislation, the continued
consolidation of payors, acceptance of our new products and
services and patent protection and litigation. For further details
and a discussion of these and other risks and uncertainties, please
see our public filings with the Securities and Exchange Commission,
including our latest periodic reports on Form 10-K and 10-Q. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
Three Months
Ended Consolidated Statements of Operations
(unaudited) (In Thousands, Except Per Share Amounts)
March 31,
2010
March 31,
2009
Revenues $ 31,816 $ 35,720 Cost of revenues 11,749
11,838 Gross profit 20,067 23,882 Gross profit
% 63.1 % 66.9 % Operating expenses: General and
administrative expense 14,136 14,087 Sales and marketing expense
7,997 7,547 Research and development expense 1,243 1,216
Amortization of intangibles 181 238 Integration, restructuring and
other charges 1,945 2,139 Total
operating expenses 25,502 25,227 (Loss) income from
operations (5,435 ) (1,345 ) Interest income, net 4
118 (Loss) income before income taxes (5,431 ) (1,227 )
Benefit (provision) from income taxes - 505
Net (loss) income $ (5,431 ) $ (722 )
Earnings per Share:
Basic $ (0.23 ) $ (0.03 ) Diluted $ (0.23 ) $ ( 0.03 )
Weighted Average Shares Outstanding: Basic 23,893 23,600 Diluted
23,893 23,600
Summary Financial Data
(In Thousands)
March 31, 2010
December 31,
2009
(unaudited) Cash and cash equivalents $ 45,255 $
49,152 Accounts receivable, net 39,313 40,885 Days sales
outstanding 113 122 Total debt - -
Three Months Ended March 31, 2010
March 31, 2009 Cash used in operations $ (2,952 ) $
(4,629 ) Capital expenditures (1,478 ) (5,594 ) Free
cash flow (4,430 ) (10,223 ) Stock compensation expense 918
1,660 Depreciation and amortization expense 3,197 2,520
Reconciliation of Non-GAAP Financial
Measures(In Thousands, Except Per Share Amounts)
In accordance with Regulation G of the Securities and Exchange
Commission, the table set forth below reconciles certain financial
measures used in this press release that were not calculated in
accordance with generally accepted accounting principles, or GAAP,
with the most directly comparable financial measure calculated in
accordance with GAAP.
Three Months Ended
(unaudited)
March 31, 2010 March 31, 2009 Operating loss –
GAAP $ (5,435 ) $ (1,345 ) Other charges (a) 2,421
2,987
Adjusted operating (loss)
income
$ (3,014 ) $ 1,642
Net loss – GAAP $ (5,431 ) $ (722 ) Other charges (net of
income tax of $0 and a benefit of $1,228) (a) 2,421
1,759
Adjusted net (loss) income $
(3,010 ) $ 1,037
Loss per diluted share – GAAP $ (0.23 ) $ (0.03 ) Other
charges per share (a) 0.10 0.07
Adjusted (loss) earnings per diluted share $
(0.13 ) $ 0.04 (a)
In the first quarter of 2010, we incurred $1.7 million of severance
and other exit cost related to the restructuring of our sales and
service organizations and management changes, as well as $0.7
million of other charges largely related to our class action and
Biotel law suits. In the first quarter of 2009 we incurred $0.4
million of costs in connection with the since terminated definitive
merger agreement to acquire Biotel, Inc., $0.5 million for special
bonus paid to the then incoming CEO and $2.1 million of
integration, restructuring and other charges.
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024